Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness

References

• Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37(21):2768–2782. doi: 10.1016/j.vaccine.2019.04.020
   PubMed Web of Science ®Google Scholar
• Olbrich KJ, Müller D, Schumacher S, et al. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421–438. doi: 10.1007/s40121-018-0213-2
   PubMed Web of Science ®Google Scholar
• Voss SS, Nielsen J, Valentiner-Branth P. Risk of sequelae after invasive meningococcal disease. BMC Infect Dis. 2022;22(1):148. doi: 10.1186/s12879-022-07129-4
   PubMed Web of Science ®Google Scholar
• Shen J, Begum N, Ruiz-Garcia Y, et al. Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review. BMC Public Health. 2022;22(1):1078. doi: 10.1186/s12889-022-13342-2
   PubMed Web of Science ®Google Scholar
• Parikh S, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–498. doi: 10.1016/j.jinf.2020.05.079
   PubMed Web of Science ®Google Scholar
• Kahler CM, Martin LE, Shih GC, et al. The (alpha2→8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun. 1998;66(12):5939–5947. doi: 10.1128/IAI.66.12.5939-5947.1998
   PubMed Web of Science ®Google Scholar
• Steenbergen SM, Vimr ER. Functional relationships of the sialyltransferases involved in expression of the polysialic acid capsules of Escherichia coli K1 and K92 and Neisseria meningitidis groups B or C. J Biol Chem. 2003;278(17):15349–15359. doi: 10.1074/jbc.M208837200
   PubMed Web of Science ®Google Scholar
• Rappuoli R, Pizza M, Masignani V, et al. Meningococcal B vaccine (4CMenB): the journey from research to real world experience. Expert Rev Vaccines. 2018;17(12):1111–1121. doi: 10.1080/14760584.2018.1547637
   PubMed Web of Science ®Google Scholar
• Deghmane AE, Taha MK. Product review on the IMD serogroup B vaccine Bexsero®. Hum Vaccin Immunother. 2022;18(1):e2020043. doi: 10.1080/21645515.2021.2020043
   PubMed Web of Science ®Google Scholar
• Perez JL, Absalon J, Beeslaar J, et al. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018;17(6):461–477. doi: 10.1080/14760584.2018.1483726
   PubMed Web of Science ®Google Scholar
• Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine. 2012;30(Suppl 2):B87–97. doi: 10.1016/j.vaccine.2012.01.033
   PubMed Web of Science ®Google Scholar
• Awanye AM, Chang CM, Wheeler JX, et al. Immunogenicity profiling of protein antigens from capsular group B Neisseria meningitidis. Sci Rep. 2019;9(1):6843. doi: 10.1038/s41598-019-43139-0
   PubMedGoogle Scholar
• Marshall GS, Fergie J, Presa J, et al. Rationale for the development of a pentavalent meningococcal vaccine: a US-focused review. Infect Dis Ther. 2022;11(3):937–951. doi: 10.1007/s40121-022-00609-9
   PubMed Web of Science ®Google Scholar
• Bekkat-Berkani R, Fragapane E, Preiss S, et al. Public health perspective of a pentavalent meningococcal vaccine combining antigens of MenACWY-CRM and 4CMenB. J Infect. 2022;85(5):481–491. doi: 10.1016/j.jinf.2022.09.001
   PubMed Web of Science ®Google Scholar
• Aye AMM, Bai X, Borrow R, et al. Meningococcal disease surveillance in the Asia-Pacific region (2020): the global meningococcal initiative. J Infect. 2020;81(5):698–711. doi: 10.1016/j.jinf.2020.07.025
   PubMed Web of Science ®Google Scholar
• Asturias EJ, Bai X, Bettinger JA, et al. Meningococcal disease in North America: updates from the global meningococcal initiative. J Infect. 2022;85(6):611–622. doi: 10.1016/j.jinf.2022.10.022
   PubMed Web of Science ®Google Scholar
• Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization. International meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24(24):5093–5107. doi: 10.1016/j.vaccine.2006.03.091
   PubMed Web of Science ®Google Scholar
• Borrow R, Taha MK, Giuliani MM, et al. Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence. J Infect. 2020;81(6):862–872. doi: 10.1016/j.jinf.2020.07.034
   PubMed Web of Science ®Google Scholar
• Obergfell KP, Seifert HS, Gellert M, et al. Mobile DNA in the pathogenic Neisseria. Microbiol Spectr. 2015;3(1):MDNA3-0015–2014. doi: 10.1128/microbiolspec.MDNA3-0015-2014
   Google Scholar
• Rotman E, Seifert HS. The genetics of Neisseria species. Ann Rev Genet. 2014;48(1):405–431. doi: 10.1146/annurev-genet-120213-092007
   PubMedGoogle Scholar
• Plikaytis BD, Stella M, Boccadifuoco G, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19(10):1609–1617. doi: 10.1128/CVI.00202-12
   PubMed Web of Science ®Google Scholar
• McNeil LK, Donald RGK, Gribenko A, et al. Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine. MBio. 2018;9(2):e00036. doi: 10.1128/mBio.00036-18
   PubMed Web of Science ®Google Scholar
• Rodrigues CMC, Jolley KA, Smith A, et al. Meningococcal Deduced Vaccine Antigen Reactivity (MenDevar) Index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J Clin Microbiol. 2020;59(1):e02161–02120. doi: 10.1128/JCM.02161-20
   PubMed Web of Science ®Google Scholar
• Muzzi A, Brozzi A, Serino L, et al. Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991–1000. doi: 10.1016/j.vaccine.2018.12.061
   PubMed Web of Science ®Google Scholar
• Medini D, Stella M, Wassil J. MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. Vaccine. 2015;33(23):2629–2636. doi: 10.1016/j.vaccine.2015.04.015
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490–19495. doi: 10.1073/pnas.1013758107
   PubMed Web of Science ®Google Scholar
• Viviani V, Biolchi A, Pizza M. Synergistic activity of antibodies in the multicomponent 4CMenB vaccine. Expert Rev Vaccines. 2022;21(5):645–658. doi: 10.1080/14760584.2022.2050697
   PubMed Web of Science ®Google Scholar
• Lodi L, Moriondo M, Nieddu F, et al. Molecular typing of group B Neisseria meningitidis’ subcapsular antigens directly on biological samples demonstrates epidemiological congruence between culture-positive and -negative cases: A surveillance study of invasive disease over a 13-year period. J Infect. 2021;82(4):28–36. doi: 10.1016/j.jinf.2020.12.034
   PubMed Web of Science ®Google Scholar
• Kleinschmidt A, Vadivelu K, Serino L, et al. Endogenous complement human serum bactericidal assay (enc-Hsba)) for vaccine effectiveness assessments against meningococcal serogroup B. NPJ Vaccines. 2021;6(1):29. doi: 10.1038/s41541-021-00286-8
   PubMed Web of Science ®Google Scholar
• Welsch JA, Senders S, Essink B, et al. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - results from a randomized, controlled, observer-blind phase II study. Vaccine. 2018;36(35):5309–5317. doi: 10.1016/j.vaccine.2018.07.016
   PubMed Web of Science ®Google Scholar
• Muzzi A, Bodini M, Topaz N, et al. Genetic features of a representative panel of 110 meningococcal B isolates to assess the efficacy of meningococcal B vaccines. mSphere. 2022;7(5):e0038522. doi: 10.1128/msphere.00385-22
   PubMed Web of Science ®Google Scholar
• Harris SL, Tan C, Perez J, et al. Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine. NPJ Vaccines. 2020;5(1):8. doi: 10.1038/s41541-019-0154-0
   PubMed Web of Science ®Google Scholar
• Findlow J, Balmer P, Borrow R. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. Hum Vaccin Immunother. 2019;15(10):2491–2500. doi: 10.1080/21645515.2019.1593082
   PubMed Web of Science ®Google Scholar
• Siggins MK, MacLennan CA. An adsorption method to prepare specific antibody-depleted normal human serum as a source of complement for human serum bactericidal assays for Salmonella. Vaccine. 2021;39(51):7503–7509. doi: 10.1016/j.vaccine.2021.10.023
   PubMed Web of Science ®Google Scholar
• Brookes C, Kuisma E, Alexander F, et al. Development of a large scale human complement source for use in bacterial immunoassays. J Immunol Methods. 2013;391(1–2):39–49. doi: 10.1016/j.jim.2013.02.007
   PubMed Web of Science ®Google Scholar
• Alexander F, Brunt E, Humphries H, et al. Generation of a universal human complement source by large-scale depletion of IgG and IgM from pooled human plasma. Methods Mol Biol. 2022;2414:341–362.
   PubMedGoogle Scholar
• Tozer SJ, Smith HV, Whiley DM, et al. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: concordant predictions between MATS and genetic MATS. Hum Vaccin Immunother. 2021;17(9):3230–3238. doi: 10.1080/21645515.2021.1904758
   PubMed Web of Science ®Google Scholar
• Tsang RSW, Law DKS, De Paola R, et al. Culture-confirmed invasive meningococcal disease in Canada, 2010 to 2014: Characterization of serogroup B Neisseria meningitidis strains and their predicted coverage by the 4CMenB vaccine. mSphere. 2020;5(2):e00883–00819. doi: 10.1128/mSphere.00883-19
   PubMed Web of Science ®Google Scholar
• Waśko I, Gołębiewska A, Kiedrowska M, et al. Genetic variability of polish serogroup B meningococci (2010-2016) including the 4CMenB vaccine component genes. Vaccine. 2020;38(8):1943–1952. doi: 10.1016/j.vaccine.2020.01.021
   PubMed Web of Science ®Google Scholar
• Mulhall RM, Bennett D, Cunney R, et al. Potential coverage of the 4CMenB vaccine against invasive serogroup B Neisseria meningitidis isolated from 2009 to 2013 in the Republic of Ireland. mSphere. 2018;3(4):e00196–00118. doi: 10.1128/mSphere.00196-18
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–4974. doi: 10.1016/j.vaccine.2013.08.006
   PubMed Web of Science ®Google Scholar
• Stella M, Giuliani M, Biolchi A, et al. Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269. Hum Vaccin Immunother. 2020;16(4):945–948. doi: 10.1080/21645515.2019.1688039
   PubMed Web of Science ®Google Scholar
• Abad R, Biolchi A, Moschioni M, et al. A large portion of meningococcal antigen typing system-negative meningococcal strains from Spain is killed by sera from adolescents and infants immunized with 4CMenB. Clin Vaccine Immunol. 2015;22(4):357–360. doi: 10.1128/CVI.00669-14
   PubMed Web of Science ®Google Scholar
• Tzanakaki G, Xirogianni A, Tsitsika A, et al. Estimated strain coverage of serogroup B meningococcal vaccines: A retrospective study for disease and carrier strains in Greece (2010-2017). Vaccine. 2021;39(11):1621–1630. doi: 10.1016/j.vaccine.2021.01.073
   PubMed Web of Science ®Google Scholar
• Bettinger JA, Liberator P, Halperin SA, et al. Estimated susceptibility of Canadian Meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp). Vaccine. 2020;38(8):2026–2033. doi: 10.1016/j.vaccine.2019.12.051
   PubMed Web of Science ®Google Scholar
• Guiducci S, Moriondo M, Nieddu F, et al. Culture and real-time polymerase chain reaction sensitivity in the diagnosis of invasive meningococcal disease: does culture miss less severe cases? PLoS One. 2019;14(3):e0212922. doi: 10.1371/journal.pone.0212922
   PubMed Web of Science ®Google Scholar
• Heinsbroek E, Ladhani S, Gray S, et al. Added value of PCR-testing for confirmation of invasive meningococcal disease in England. J Infect. 2013;67(5):385–390. doi: 10.1016/j.jinf.2013.06.007
   PubMed Web of Science ®Google Scholar
• Hong E, Terrade A, Muzzi A, et al. Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France. Hum Vaccin Immunother. 2021;17(12):5614–5622. doi: 10.1080/21645515.2021.2004055
   PubMed Web of Science ®Google Scholar
• Bodini M, Brozzi A, Giuliani M, et al. Genomic characterization of invasive meningococcal serogroup B isolates and estimation of 4CMenB vaccine coverage in Finland. mSphere. 2020;5(5):e00376–00320. doi: 10.1128/mSphere.00376-20
   PubMed Web of Science ®Google Scholar
• Freudenburg-de Graaf W, Knol MJ, van der Ende A. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands. Vaccine. 2020;38(49):7850–7857. doi: 10.1016/j.vaccine.2020.10.008
   PubMed Web of Science ®Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, et al. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30. doi: 10.1007/s40265-013-0155-7
   PubMed Web of Science ®Google Scholar
• Rajam G, Stella M, Kim E, et al. Meningococcal Antigen Typing System (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States. mSphere. 2017;2(6):e00261–00217. doi: 10.1128/mSphere.00261-17
   PubMed Web of Science ®Google Scholar
• Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29–30):4739–4744. doi: 10.1016/j.vaccine.2011.04.092
   PubMed Web of Science ®Google Scholar
• Biolchi A, Tomei S, Santini L, et al. Four-component meningococcal serogroup B vaccine induces antibodies with bactericidal activity against diverse outbreak strains in adolescents. Pediatr Infect Dis J. 2021;40(2):e66–e71. doi: 10.1097/INF.0000000000002957
   PubMed Web of Science ®Google Scholar
• Rossi R, Beernink PT, Giuntini S, et al. Susceptibility of meningococcal strains responsible for two serogroup B outbreaks on U.S. university campuses to serum bactericidal activity elicited by the MenB-4C vaccine. Clin Vaccine Immunol. 2015;22(12):1227–1234. doi: 10.1128/CVI.00474-15
   PubMed Web of Science ®Google Scholar
• Lujan E, Partridge E, Giuntini S, et al. Breadth and duration of meningococcal serum bactericidal activity in health care workers and microbiologists immunized with the MenB-FHbp vaccine. Clin Vaccine Immunol. 2017;24(8):e0012117. doi: 10.1128/CVI.00121-17
   Google Scholar
• Lujan E, Winter K, Rovaris J, et al. Serum bactericidal antibody responses of students immunized with a meningococcal serogroup B vaccine in response to an outbreak on a university campus. Clin Infect Dis. 2017;65(7):1112–1119. doi: 10.1093/cid/cix519
   PubMed Web of Science ®Google Scholar
• Chang HY, Vuong J, Hu F, et al. Distribution of Neisseria meningitidis serogroup B (NmB) vaccine antigens in meningococcal disease causing isolates in the United States during 2009-2014, prior to NmB vaccine licensure. J Infect. 2019;79(5):426–434. doi: 10.1016/j.jinf.2019.09.001
   PubMed Web of Science ®Google Scholar
• Mowlaboccus S, Perkins TT, Smith H, et al. Temporal changes in BEXSERO® antigen sequence type associated with genetic lineages of Neisseria meningitidis over a 15-year period in Western Australia. PLoS One. 2016;11(6):e0158315. doi: 10.1371/journal.pone.0158315
   PubMed Web of Science ®Google Scholar
• Bambini S, Piet J, Muzzi A, et al. An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands. PLoS One. 2013;8(5):e65043. doi: 10.1371/journal.pone.0065043
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Effectiveness of GlaxoSmithKline biologicals S.A’s meningococcal group B and combined ABCWY vaccines in healthy adolescents and young adults; 2022 [cited 2023 Apr 13]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04502693
   Google Scholar
• Zlotnick GW, Jones TR, Liberator P, et al. The discovery and development of a novel vaccine to protect against Neisseria meningitidis serogroup B disease. Hum Vaccin Immunother. 2015;11(1):5–13. doi: 10.4161/hv.34293
   PubMed Web of Science ®Google Scholar
• Ostergaard L, Vesikari T, Absalon J, et al. A bivalent meningococcal B vaccine in adolescents and young adults. N Engl J Med. 2017;377(24):2349–2362. doi: 10.1056/NEJMoa1614474
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. MenABCWY noninferiority study in healthy participants ≥10 to <26 years of age; 2022 [cited 2023 Apr 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT04440163?cond=menabcwy&draw=2&rank=3
   Google Scholar
• Pfizer Inc. Pfizer announces positive top-line results from phase 3 trial of pentavalent meningococcal vaccine candidate (MenABCWY) in adolescents; 2022 [cited 2023 Apr 13]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-results-phase-3-trial-0
   Google Scholar